Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02792114 · ClinicalTrials.gov registry record · Phase 1
T-Cell Therapy for Advanced Breast Cancer
A Phase 1 study of Breast Cancer and Metastatic HER2-negative Breast, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 186
- Enrollment target
- 7
- Study locations
NCT02792114: Active Phase 1 study of Breast Cancer and Metastatic HER2-negative Breast, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02792114 is a Phase 1 study of Breast Cancer and Metastatic HER2-negative Breast that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 186 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02792114, a Phase 1 study of Breast Cancer and Metastatic HER2-negative Breast, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 186 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test the safety of different doses of specially prepared T cells collected from the blood. The investigators want to find a safe dose of these modified T cells for patients who have metastatic HER2-negative breast cancer.
Primary Outcome
We have designed the dose-escalation using a standard 3+3 design. In this design, patients will be treated in sequential groups of 3 to 6 patients per T cell dose. With 4 dose levels, the projected trial size for this study is a minimum of 4 and a maximum of 24 patients.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG AP1903
- BIOLOGICAL Mesothelin-targeted T cells
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center at Commack (Consent and follow-up only) - Commack
- Memorial Sloan Kettering Westchester (Consent and follow-up only) - East White Plains
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Consent and Follow-Up only) - Uniondale
New Jersey
- Memorial Sloan Kettering Cancer Center (Consent and follow-up only) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent and follow-up only) - Middletown
- Memorial Sloan Kettering Bergen (Consent and follow-up only) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2016-06 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What the registry record for NCT02792114 still lists
NCT02792114 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT02792114 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT02792114 about?
NCT02792114 is a clinical study titled "T-Cell Therapy for Advanced Breast Cancer". The purpose of this study is to test the safety of different doses of specially prepared T cells collected from the blood. The investigators want to find a safe dose of these modified T cells for patients who have metastatic HER2-negative breast cancer.
What is the current status of trial NCT02792114?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 186 participants. The study started on 2016-06. Estimated completion is 2026-06.
What conditions does trial NCT02792114 study?
This clinical trial studies the following conditions: Breast Cancer, Metastatic HER2-negative Breast.
What interventions are being tested in trial NCT02792114?
The interventions under investigation include: Cyclophosphamide (DRUG), AP1903 (DRUG), Mesothelin-targeted T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02792114?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02792114 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02792114's enrollment target sits among peer trials
186 396th of 1224 higher than 829 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia